Audentes Therapeutics   Report issue

For profit Phase 2
Founded: San Francisco CA United States (2013)
Status: Acquired by Astellas (2019) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2017
NCT03199469
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Audentes Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (4)

at132 (1 trial)

at845 (1 trial)

scaav9.u7.acca (1 trial)

Volrubigene ralaparvovec (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 2)

Crigler-Najjar Syndrome (Phase 2)

Glycogen Storage Disease Type II (Phase 2)

Muscular Diseases (Phase 2)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Myopathies, Structural, Congenital (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4